HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Malignant hyperthermia susceptibility type 1

Also Known As:

Malignant Hyperthermia, Susceptibility To, 1

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Signs and Symptoms Pathological Conditions
- Pathologic Processes: 10023
  - Intraoperative Complications: 3522
    - Malignant Hyperthermia: 2449
      - Malignant hyperthermia susceptibility type 1: 1
  - Postoperative Complications
    - Malignant Hyperthermia: 2449
      - Malignant hyperthermia susceptibility type 1: 1
- Signs and Symptoms
  - Body Temperature Changes: 152
    - Hyperthermia: 14068
      - Malignant Hyperthermia: 2449
        Malignant hyperthermia susceptibility type 1: 1

Related Diseases

1.	Congenital Structural Myopathies (Centronuclear Myopathy)
2.	Central Core Myopathy (Central Core Disease)
3.	Muscular Diseases (Myopathy)
4.	Minicore Myopathy with External Ophthalmoplegia

Experts

1.	Atwal, Paldeep S: 1 article (05/2017)
2.	Blackburn, Patrick R: 1 article (05/2017)
3.	Boczek, Nicole J: 1 article (05/2017)
4.	Cousin, Margot A: 1 article (05/2017)
5.	Dimberg, Elliot L: 1 article (05/2017)
6.	Gass, Jennifer M: 1 article (05/2017)
7.	Jackson, Jessica L: 1 article (05/2017)
8.	Kennelly, Kathleen D: 1 article (05/2017)
9.	Klee, Eric W: 1 article (05/2017)
10.	Macklin, Sarah: 1 article (05/2017)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Malignant hyperthermia susceptibility type 1:

1.	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 05/01/2017 - "Pathogenic variants in ryanodine receptor 1 (RYR1, MIM# 180901) are the cause of congenital myopathy with fiber-type disproportion, malignant hyperthermia susceptibility type 1, central core disease of muscle, multiminicore disease and other congenital myopathies. "